Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia

M Martínez-Castillo, L Gómez-Romero, H Tovar… - Leukemia Research, 2023 - Elsevier
Use of the potent tyrosine kinase inhibitor imatinib as the first-line treatment in chronic
myeloid leukemia (CML) has decreased mortality from 20% to 2%. Approximately 30% of …

[HTML][HTML] Frequencies of BCR:: ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis

P Romero-Morelos, AL González-Yebra… - Genes, 2024 - mdpi.com
Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome and
distinct BCR:: ABL1 gene transcripts. We assessed the frequencies of these transcripts in …

[PDF][PDF] Autoras

C de Laboratorio Clínico - 2019 - dspace.ucuenca.edu.ec
Chronic myeloid leukemia is a malignant hematologic malignancy that arises from the
reciprocal translocation between chromosomes 9 and 22. It represents between 15 to 20 …

[PDF][PDF] Facultad de Ciencias Médicas Escuela de Tecnología Médica

CDET FÍSICA - 2018 - dspace.ucuenca.edu.ec
Objetivo: Determinar el sedentarismo y obesidad central en pacientes con hipertensión
arterial y diabetes mellitus tipo 2 en el centro de salud Carlos Elizalde. Método y materiales …